(RELX) Relx - Ratings and Ratios
Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US7595301083
RELX: Risk Analytics, Scientific Data, Legal Tools, Exhibition Platforms
RELX PLC, operating through its subsidiaries, delivers advanced information-based analytics and decision-making tools tailored for professional and business clients across North America, Europe, and global markets. The companys operations are organized into four distinct segments: Risk, Scientific, Technical & Medical, Legal, and Exhibitions. The Risk segment provides specialized analytics that integrate public and industry-specific data with cutting-edge technology to help clients assess and predict risks, particularly in sectors like finance and insurance. The Scientific, Technical & Medical segment offers comprehensive datasets and research tools that aid scientists and healthcare professionals in advancing medical breakthroughs and improving patient outcomes. The Legal segment furnishes legal and regulatory insights, enhancing decision-making processes and productivity for legal professionals. The Exhibitions segment combines in-person events with digital tools to facilitate market learning, product sourcing, and transactions across various industries. Formerly known as Reed Elsevier PLC, the company rebranded as RELX PLC in July 2015. Established in 1903, RELX PLC is headquartered in London, UK, and is accessible online at https://www.relx.com.
From a technical standpoint, RELX shares are currently trading at $52.20, with a 20-day average volume of 620,092. The stock is above its 20-day ($49.73), 50-day ($49.47), and 200-day ($47.47) moving averages, signaling positive momentum. The Average True Range (ATR) of 1.09 indicates moderate volatility. Support levels are identified at 50.4, 48.7, 47.1, 45.2, and 40.4. Fundamental analysis highlights a market cap of $90.356B, with a trailing P/E of 37.14 and a forward P/E of 28.41. The price-to-book ratio stands at 20.19, and the price-to-sales ratio is 9.58. Notably, the return on equity (RoE) is 106.72%, reflecting strong profitability relative to shareholder equity.
Over the next three months, RELX is expected to maintain its upward trajectory, supported by its strong financials and market position. The stocks current price above key moving averages suggests continued bullish momentum. However, with a high P/E ratio, investors should monitor for potential volatility. The companys high return on equity and established market presence further bolster its outlook. Support at 50.4 may act as a floor if the stock retraces, providing a buying opportunity. Overall, RELX is well-positioned for growth, driven by its diverse segments and robust financial health.
Additional Sources for RELX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RELX Stock Overview
Market Cap in USD | 96,167m |
Sector | Industrials |
Industry | Specialty Business Services |
GiC Sub-Industry | Research & Consulting Services |
IPO / Inception | 1994-10-07 |
RELX Stock Ratings
Growth Rating | 89.1 |
Fundamental | 88.8 |
Dividend Rating | 55.7 |
Rel. Strength | 21.4 |
Analysts | 4/5 |
Fair Price Momentum | 58.60 USD |
Fair Price DCF | 54.75 USD |
RELX Dividends
Dividend Yield 12m | 2.67% |
Yield on Cost 5y | 6.38% |
Annual Growth 5y | 5.19% |
Payout Consistency | 88.4% |
RELX Growth Ratios
Growth Correlation 3m | 1.5% |
Growth Correlation 12m | 80.9% |
Growth Correlation 5y | 93.8% |
CAGR 5y | 20.30% |
CAGR/Max DD 5y | 0.77 |
Sharpe Ratio 12m | 1.18 |
Alpha | 22.70 |
Beta | 0.559 |
Volatility | 32.20% |
Current Volume | 0k |
Average Volume 20d | 620.1k |
As of April 21, 2025, the stock is trading at USD 52.20 with a total of 0 shares traded.
Over the past week, the price has changed by +4.15%, over one month by +4.63%, over three months by +5.35% and over the past year by +27.21%.
Yes, based on ValueRay Fundamental Analyses, Relx (NYSE:RELX) is currently (April 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 88.79 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RELX as of April 2025 is 58.60. This means that RELX is currently undervalued and has a potential upside of +12.26% (Margin of Safety).
Relx has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy RELX.
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, RELX Relx will be worth about 63.8 in April 2026. The stock is currently trading at 52.20. This means that the stock has a potential upside of +22.26%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 53.2 | 2% |
Analysts Target Price | 50.1 | -4% |
ValueRay Target Price | 63.8 | 22.3% |